We are not currently seeking FDA approval for RC110 as we don’t have the resources to advance both RC110 and RC220 without diluting our shareholders to oblivion.
If you understand how the drug development process works you would understand that closeness to FDA approval is not an important metric, what matters is clinical risk and market potential. This is why IMU were able to buy their most advanced clinical program (the Azer-cel Car-T) for next to nothing and a bunch of biobucks.
On the metrics of clinical risk and market potential I would take RC220 over anything owned by any other ASX listed biotech. My job is to increase the number of investors who share this belief.
RAC - Charts & Price Action, page-18207
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.89 |
Change
0.120(6.80%) |
Mkt cap ! $321.0M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.93 | $1.78 | $563.4K | 302.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 108 | $1.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.90 | 4926 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |